NTLA β€” INTELLIA THERAPEUTICS INC

Ownership history in Second Line Capital, LLC  Β·  4 quarters on record

This page tracks every 13F SEC filing in which Second Line Capital, LLC reported a position in INTELLIA THERAPEUTICS INC (NTLA). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β€” sourced directly from SEC EDGAR 13F filings.

πŸ” Peak position
0.41% (2024 Q4)
πŸ“Š Avg. % of fund
0.23%
πŸ“… First filed
2024 Q4
πŸ“… Last filed
2025 Q3
⏱ Quarters held
4

Position Intelligence

Second Line Capital, LLC Γ— NTLA AI Analytics

πŸ“ˆ Second Line Capital, LLC outperformed the S&P 500 by +83.2% annually on this NTLA position. Timing score: 0% (0/3 decisions correct). Average cost basis: $11.66. Maximum drawdown during holding period: –39.0%.

πŸ“ˆ Position Alpha vs SPY
+83.2%
annualised excess return

πŸ”₯ Exceptional β€” beat the S&P 500 by 83.2% per year on this position.
3 quarters analyzed

⏱️ Timing Score
0%

⚠️ Poor timing β€” buys often preceded drops, trims preceded rallies.
0 of 3 add/trim decisions correct

πŸ’° Entry Quality
$11.66
+48.1% vs current ($17.27)

Best entry: $11.66 (2024 Q4)  Β·  Worst: $11.66 (2024 Q4)

πŸ›‘οΈ Drawdown Resilience
–39.0%
max drawdown while held

πŸ’ͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.

πŸ’ͺ Fund Conviction
33%
buy-side decisions

1 add Β· 2 trims. Bought during 0 of 1 down-price quarters. πŸ“‰ Predominantly trimming β€” distribution phase.

πŸ“‘ Position Trajectory
β†’ Stable
last 4–5 quarters trend

βš–οΈ Portfolio weight has remained relatively stable β€” conviction maintained.
Currently 0.23% of portfolio

⚠ Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ— 4 (annualised). Not investment advice.

% of Fund (quarterly)    NTLA price (monthly, adj. close)
πŸ“‹ Quarterly Holdings History 4 quarters  β–Ύ
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 UNCHANGED 63,027 β€” 0% 0.23% $1.1M $17.27
2025 Q2 REDUCED 63,027 -16,672 -20.9% 0.14% $591K $9.38
2025 Q1 REDUCED 79,699 -51,423 -39.2% 0.15% $567K $7.11
2024 Q4 INITIATED 131,122 β€” β€” 0.41% $1.5M $11.66

🏒 Other funds also holding NTLA

As of 2025 Q4 β€” sorted by position size

REGENERON PHARMACEUTICALS, INC. 98.49% Discovery Value Fund 3Y 7Y 2.35% Birchview Capital, LP 3Y 7Y 1.66% ARK Investment Management LLC 3Y 7Y 0.85% Orchard Capital Management, LLC 3Y 0.64% IQ EQ FUND MANAGEMENT (IRELAND) Ltd 3Y 7Y 0.45% HIMENSION CAPITAL (SINGAPORE) PTE. LTD. 3Y 0.32% Amova Asset Management Americas, Inc. 3Y 7Y 0.23% Elmwood Wealth Management, Inc. 3Y 7Y 0.22% Headlands Technologies LLC 3Y 0.18%
← Back to Second Line Capital, LLC Holdings